Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Their pipeline has recently expanded and now includes two clinical-stage products with common regulatory and development strategies.

Oncternal Therapeutics cutting-edge scientific approach is focused on targets that are uniquely expressed within cancer cells, resulting in highly targeted new therapies. They also apply a variety of therapeutic strategies to address different medical challenges - from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T).

Oncternal Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics, Health Diagnostics, Oncology sector. The company focuses on Biotechnology and has secured $18.5B in funding across 140 round(s). With a team of 11-50 employees, Oncternal Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Oncternal Therapeutics, raised $3.1M. Discover more about their projects, partnerships, and impact on our platform.